AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

14 recruiting trials

for Refractory Myasthenia Gravis

Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases NCT07470151NA1 site📍 Wuhan Union Hospital, Tongji Medical College, Huazhong University… · Tests: EVM18001 Injection Universal Chimeric Antigen Receptor T-Cell (UCAR T-cell) Therapy Targeting CD19/B Cell Maturation Antigen (CD19/BCMA) in Patients With r/r Neurological Autoimmune Diseases NCT06939166EARLY Phase 11 site📍 Tianjin Tianjin Huanhu Hospital · Tests: UCAR T-cell GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103) NCT07058298EARLY Phase 11 site📍 Wuhan Daishi Tian · Tests: GC012F injection Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases NCT07085676Phase 11 site📍 Jerusalem Polina Stepensky · Tests: HBI0101 CART Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG) NCT07413835NA1 site📍 Xuzhou The Affiliated Hospital of Xuzhou Medical University · Tests: HN2302 Injection A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy NCT06249438Phase 11 site📍 Shanghai RenJi Hospital · Tests: CD20/BCMA-directed CAR-T cells A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis NCT06688435Phase 11 site📍 Jinan CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Tests: SYS6020 injection, SYS6020 injection, SYS6020 injection PANORAMA: Neuromuscular Organoids for Refractory AChR+ Myasthenia Gravis NCT07717281n/a1 site📍 Milan Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis NCT06371040Phase 11 site📍 Xi'an Ting Chang, MD · Tests: CD19-BCMA Targeted CAR-T Dose 1, CD19-BCMA Targeted CAR-T Dose 2, CD19-BCMA Targeted CAR-T Dose 2 Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment NCT07304154Phase 110 sites📍 Newport Beach📍 Palo Alto📍 New York Kite, A Gilead Company · Tests: KITE-363, Fludarabine, Cyclophosphamide CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases NCT07337785EARLY Phase 11 site📍 Wuhan Tongji Hospital · Tests: CD19/BCMA-targeted CAR-T cells, Lymphodepleting Conditioning Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System NCT04561557EARLY Phase 11 site📍 Wuhan Tongji Hospital · Tests: CT103A cells, Cyclophosphamide and fludarabine Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases NCT07022197Phase 1, Phase 21 site📍 Tianjin Tianjin Medical University General Hospital · Tests: BAFF-R CART Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases. NCT07526493Phase 11 site📍 Wuhan Tongji Hospital · Tests: Universal CD19 CAR-γδT Cell Injection, Cyclophosphamide, Fludarabine
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy